Yusuke Nakamura to Esophageal Neoplasms
This is a "connection" page, showing publications Yusuke Nakamura has written about Esophageal Neoplasms.
Connection Strength
2.597
-
Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects. Ann Surg. 2022 01 01; 275(1):e155-e162.
Score: 0.685
-
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012 Jul 09; 10:141.
Score: 0.355
-
From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008 Feb; 56(2):43-53.
Score: 0.262
-
Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol. 2006 Jun; 28(6):1375-84.
Score: 0.232
-
Demographic and lifestyle factors and survival among patients with esophageal and gastric cancer: The Biobank Japan Project. J Epidemiol. 2017 Mar; 27(3S):S29-S35.
Score: 0.122
-
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 2014 Apr 03; 12:84.
Score: 0.100
-
Identification of a novel oncogene, MMS22L, involved in lung and esophageal carcinogenesis. Int J Oncol. 2012 Oct; 41(4):1285-96.
Score: 0.089
-
Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis. Cancer Sci. 2012 Mar; 103(3):577-86.
Score: 0.086
-
Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res. 2010 Jan 01; 16(1):226-39.
Score: 0.074
-
Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology. 2009 Nov; 137(5):1768-75.
Score: 0.073
-
Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009 Aug; 100(8):1502-9.
Score: 0.071
-
Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res. 2009 Jan 01; 15(1):256-66.
Score: 0.070
-
Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci. 2008 Jul; 99(7):1448-54.
Score: 0.066
-
Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer. 2008 Feb 01; 122(3):587-94.
Score: 0.065
-
Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 2007 Dec 15; 67(24):11601-11.
Score: 0.065
-
Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007 Mar 15; 67(6):2517-25.
Score: 0.061
-
Tumor suppressive role of a 2.4 Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma. Oncogene. 2005 Jan 20; 24(4):697-705.
Score: 0.053
-
Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res. 2004 Oct 01; 10(19):6437-48.
Score: 0.052
-
Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov; 98(11):1803-8.
Score: 0.016